Cambridge Investment Research Advisors’s Cytokinetics CYTK Stock Holding History

Cambridge Investment Research Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$212K	Buy	+2,490	New	+$179K	﹤0.01%	3511

Other funds holding CYTK

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

EOJOAM

E. Ohman J:or Asset Management Stockholm, Sweden $4.3B AUM 29.55% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

MCP

Mirador Capital Partners Pleasanton, California $817M AUM 42.46% 1-Year Est. Return

Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

PCM

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

CFM

Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return

Amalgamated Bank New York $14.5B AUM 44.3% 1-Year Est. Return

Cambridge Investment Research Advisors's CYTK Position: Q2 2026 in Review

Cambridge Investment Research Advisors opened a new position in Cytokinetics (CYTK) in Q2 2026: 2,490 shares worth $212K. The stake represents ﹤0.01% of the portfolio and ranks #3511 among its holdings.

99 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Cambridge Investment Research Advisors held 2,490 shares of Cytokinetics worth $212K as of Q2 2026.
Cytokinetics was a new Cambridge Investment Research Advisors position in Q2 2026.
Cytokinetics made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #3511 holding.
99 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.